NEW YORK, May 12, 2016 /PRNewswire/ -- Extra value: One year of free online updates included with this product"Target Atlasin Leukemia: A Competitive Outlook" helps you to understand the complex world of commercial development in leukemia by identifying the most promising Target Approaches in development today from your competitors and prospective partners and revealing
"Target Atlas in Leukemia: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, integrated with drug pipeline information covering commercial developments of molecular drug targets in leukemia from 332 companies plus partners. With the "Target Atlas in Leukemia: A Competitive Outlook" at your fingertips, you are able to identify opportunities and avoid pitfalls in the area of leukemia. The Target Atlas provides unparalleled, in-depth R&D analysis for each of the 5 approved drug targets and 325 targets in development in leukemia whether they are established or novel, first-in-class drug targets. You can analyze these as both Single Targets as well as Target Clusters, which is a great feature when you are dealing with many targets at the same time.Furthermore, this target analyzer comes integrated with full drug pipeline information for 611 drugs which lets you effortlessly access relevant, in-depth information about each drug linked to a specific target.
The Target Atlas gives you the information you need to make successful decisions and understand fully what is happening in the field of leukemia from a target and drug development perspective. This is information you can't get anywhere else and in addition, you will stay up to date as your Target Atlas comes powered with 1 year of free online updates!"Target Atlas in Leukemia: A Competitive Outlook" is a Great Product for:* Target Scouting* First-in-class analysis* R&D profiling* Target-Target Interaction Analysis* Mapping the competitionWho is Already Using the Target Atlas Series to Aid Their Decision-Making?* CEO and CSO's* Clinical and preclinical development specialists.* Business development and licensing specialists* Search and Evaluation departments* Corporate strategy, product and portfolio analysts* Venture capital and Investment SpecialistsGain Insights into Leukemia TargetsAll of the drug targets pursued for the treatment of leukemia are proteins. The 322 separate human protein targets among leukemia drugs represent 69 different types of molecular functions and are directly related to the mechanism of action for these drugs.Get the full picture of the target landscape of leukemia so that you are basing your decisions on all the available information, independently acquired for you by our expert team of analysts.Using the Target Atlas allows you to not only save time, but also leads to you conducting better assessments which you can back up with real data. A built-in infographics module makes it easy to export graphs and charts to include in your own reports and presentations to other stakeholders.Additional Key Facts of Targets in Leukemia Include:Targets with mutations #317Targets with tumor expression profiles #304Targets which are strongly implicated with certain types of cancer #73Targets with biological structures #256In the Target Atlas you will get independently sourced information in a context found nowhere else, benefiting your research, analyses and decisions.
Perform Target Cluster AnalysisYou can simultaneously access any number of the total 330 targets covered in this product by using up to 24 different pipeline parameters, including: Target, Company, Stage of Development, Compound Type, Indications, Pathway, Mutation, Subcellular Location, etc.On any Target Query the Target Cluster Analysis will deliver:Target Summary - Outlining the number and identity of Targets, Target Approaches, Drugs, Indications and Companies in both Tables and Charts.Target - All targets sortable by number of Drugs, Indications, Companies and Highest Stage of Development. Access to graphical breakdowns of targets by Stage, Compound Type, Indication and Company.Target Approach* - All Target Approaches sortable by number of Drugs, Indications, Companies and Highest Stage of Development. Access to graphical breakdowns of Target Approaches by Stage, Compound Type, Indication and Company.Competitive Review - First-in-Class analysis of all Target Approaches by stage of development or independent of stage. Based upon the 24 filter settings available, identify the number and identity of unique Target Approaches in cancer in any context. * A Target Approach visualizes each drug according to its complete range of targets, hence providing a superior sharpness in target comparison among drugs. Each Target Approach represents a distinct way of attacking cancer.Generate 330 Target Analysis Reports, Tailored to Your Specific InterestYou can generate a target report on any of the 330 included targets in "Target Atlas in Leukemia: A Competitive Outlook". Furthermore, you can tailor any of these reports based on Companies, Type of Compounds, Indications, Stage of Development, etc.Each Target Analysis Report Includes:- Gene/Protein Overview- Mutational Review- Pathway Matching- Tumor Expression Profiles- Target-Target Analysis- Target Approach Analysis- R&D Progression AnalysisAccess to Pipeline Information on 611 Leukemia DrugsThe Target Atlas comes integrated with in-depth drug pipeline information. With a simple click you can effortlessly access relevant information about each drug included in any target report. A drug profile includes**:- Drug Name & Synonyms- Principal Company & Partners- Drug Description- Fillings and Approvals- Sales Figures- Deals and Licensing- Compound Data- Patent Data- Target and Molecular Function of Target- Target Localization- Mutational Profiling- Biological Structures- Target Expression Profiles- Targeted Pathways- Mechanism of Action- Developmental Projects- Developmental information (Discovery-Phase IV)
**Information included in a drug profile is dependent on the drug's maturity and other factors.Cut Your Opportunity Costs Today Would your work benefit from having a full understanding of the development within leukemia from a Target/Drug point of view? When you consider the substantial value and effort involved in the projects you are working on, does it make sense to have a third-party analysis tool to validate and help guide your decision making with confidence?If yes, then purchasing the "Target Atlas in Leukemia: A Competitive Outlook" represents a unique opportunity to get these in-depth insights today. With one year of free online updates and fully exportable data and charts, you will have access to the latest information and can easily present your findings to your colleagues and stakeholders.
Welcome to having the world of leukemia at your fingertips with "Target Atlas in Leukemia: A Competitive Outlook"!System Requirements- Operating system: Windows (2000/XP/Vista/7/8) and Mac Users are offered Online Access Only- Browser Application (Internet Explorer)- Internet access (to access related internet resources)Read the full report: http://www.reportlinker.com/p03641142-summary/view-report.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com
__________________________Contact Clare: email@example.comUS: (339)-368-6001Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/target-atlas-in-leukemia-a-competitive-outlook-300268151.html
Subscribe to our Free Newsletters!
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Inborn errors of metabolism are genetic disorders that hamper the body''s metabolism resulting in ...
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...View All